Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Breakpoint Cluster Region Protein-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-Abl)
- Target
- BCR-Abl
- Molecular classification
- Fusion Protein, Tyrosine Kinase, Oncoprotein
01
Overview
The BCR-Abl protein is a fusion oncoprotein resulting from the translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9, forming the Philadelphia chromosome. It exhibits constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation and survival, primarily associated with chronic myelogenous leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). Targeting its aberrant kinase activity is the basis for therapies such as imatinib.
- Other names
- BCR/ABL fusion proteinPhiladelphia chromosome proteinp210 BCR-ABLp190 BCR-ABLp230 BCR-ABL
02
Mechanism of action
Tyrosine kinase inhibition
03
Biological functions
Signal transductionCell proliferationApoptosis inhibitionGTPase regulationKinase activity regulation
04
Disease associations
CancerChronic Myelogenous Leukemia (CML)Acute Lymphoblastic Leukemia (ALL)
05
Safety considerations
Resistance to tyrosine kinase inhibitorsOff-target effects of tyrosine kinase inhibitorsCardiovascular side effectsDrug-drug interactions
06
Interacting drugs
5 more in the full profile.
07
Biomarkers
BCR-Abl transcript levelsBCR-Abl kinase domain mutations
Beyond the preview
Go deeper on Breakpoint Cluster Region Protein-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-Abl).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Breakpoint Cluster Region Protein-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-Abl).